New Delhi: Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.

“Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing,” the US embassy in India said in a tweet on Wednesday.

India’s first indigenously developed RBD protein subunit vaccine, Biological E’s Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.

CORBEVAX is a protein sub-unit vaccine, developed from a component of the spike protein on the virus’s surface, which helps the body build the immune response against the virus. The vaccine has the Receptor Binding Domain (RBD) protein as an antigen, CpG 1018 and Aluminium hydroxide as adjuvants formulated in Tris buffer.

The Drugs Controller General of India (DCGI) recently approved Corbevax as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination (two doses) of COVAXIN or COVISHIELD vaccines for restricted use in emergency situation. 

Read also: DCGI nod to Biological E Corbevax as heterologous COVID booster

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics.
BE supplies its vaccines to more than 130 countries and its therapeutic products are sold in India and the USA, Europe. BE currently has 8 WHO-prequalified vaccines in its portfolio and 5 USFDA approved Injectables.

Leave a Reply

Your email address will not be published. Required fields are marked *